Mechanosensitive Non-Coding RNAs in Cardiovascular Disease: Mechanisms, Therapeutic Targeting and Cardiac Delivery
- 1Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy
- 2Department of Medicine, Libera Università Mediterranea (LUM) University, 70010 Casamassima, Italy
Abstract
Non-coding RNAs (ncRNAs) have emerged as major regulators of gene expression and cellular homeostasis, with growing evidence supporting their involvement in cardiovascular physiology and disease. This review summarizes the classification, mechanisms of action, and functional roles of ncRNAs, with particular focus on mechano-ncRNAs involved in cardiovascular remodeling and fibrosis. Different classes of ncRNAs are discussed in relation to their contributions to vascular, valvular, and myocardial homeostasis, as well as to pathological processes including inflammation, endothelial dysfunction, and fibrotic responses. Special emphasis is placed on biomechanical stimuli, including increased matrix stiffness, cyclic strain, and altered shear stress, which can modulate ncRNA expression and activity through mechanotransduction pathways. Notable examples of mechano-ncRNAs include miR-21, miR-29, miR-132, MIAT, MALAT1, and MEG3, which have been implicated in maladaptive cardiac remodeling and fibrosis. Concurrently, we highlight the importance of technical advances in ncRNA discovery and cardiac-specific delivery systems, including viral and nanoparticle-based vectors, for the development of ncRNA-based therapeutic strategies with potential for clinical translation. Overall, ncRNAs are shown to represent promising biomarkers and therapeutic targets in cardiovascular diseases, particularly in mechanically driven pathological conditions. However, challenges related to delivery specificity, stability, off-target effects, and safety remain and will need to be addressed to enable the clinical translation of ncRNA-based therapies in precision cardiovascular medicine.
Related
- Mechanobiology in Osteoarthritis: From Crosstalk of Mechanosensitive Signaling Pathways to the Intervention Mechanisms and Therapeutic Potential of Exercise.
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Exerkines in Cardiovascular–Kidney–Metabolic Syndrome: An Integrative Framework for Mechanisms and Therapeutic Implications—A Narrative Review
- Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
- Targeting cardiovascular immunometabolism with phytomedicines: an emerging therapeutic technique
BibTeX
@article{fancello2026mechanosensitive,
title = {{Mechanosensitive Non-Coding RNAs in Cardiovascular Disease: Mechanisms, Therapeutic Targeting and Cardiac Delivery}},
author = {Irene Fancello and Veronica Candino and Daniel Gamo Gonzalez and Maurizio Pesce and Gloria Garoffolo},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15211952},
url = {https://www.mdpi.com/2073-4409/15/21/1952},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mechanosensitive Non-Coding RNAs in Cardiovascular Disease: Mechanisms, Therapeutic Targeting and Cardiac Delivery
AU - Irene Fancello
AU - Veronica Candino
AU - Daniel Gamo Gonzalez
AU - Maurizio Pesce
AU - Gloria Garoffolo
PY - 2026
DA - 2026/10/27
JO - Cells
DO - 10.3390/cells15211952
UR - https://www.mdpi.com/2073-4409/15/21/1952
AB - Non-coding RNAs (ncRNAs) have emerged as major regulators of gene expression and cellular homeostasis, with growing evidence supporting their involvement in cardiovascular physiology and disease. This review summarizes the classification, mechanisms of action, and functional roles of ncRNAs, with particular focus on mechano-ncRNAs involved in cardiovascular remodeling and fibrosis. Different classes of ncRNAs are discussed in relation to their contributions to vascular, valvular, and myocardial homeostasis, as well as to pathological processes including inflammation, endothelial dysfunction, and fibrotic responses. Special emphasis is placed on biomechanical stimuli, including increased matrix stiffness, cyclic strain, and altered shear stress, which can modulate ncRNA expression and activity through mechanotransduction pathways. Notable examples of mechano-ncRNAs include miR-21, miR-29, miR-132, MIAT, MALAT1, and MEG3, which have been implicated in maladaptive cardiac remodeling and fibrosis. Concurrently, we highlight the importance of technical advances in ncRNA discovery and cardiac-specific delivery systems, including viral and nanoparticle-based vectors, for the development of ncRNA-based therapeutic strategies with potential for clinical translation. Overall, ncRNAs are shown to represent promising biomarkers and therapeutic targets in cardiovascular diseases, particularly in mechanically driven pathological conditions. However, challenges related to delivery specificity, stability, off-target effects, and safety remain and will need to be addressed to enable the clinical translation of ncRNA-based therapies in precision cardiovascular medicine.
SN - 2073-4409
ER -